NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-21-299 from the NIH Guide for Grants and Contracts. The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.
Funding Opportunity PAR-21-300 from the NIH Guide for Grants and Contracts. The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.
Funding Opportunity RFA-HL-22-004 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support applications that propose the establishment of a Hemophilia A Analytical Cohort Research Program (HARP) that will: 1) collaborate with an established consortium of clinical centers to support the recruitment, enrollment, and follow-up of an antenatal/ neonatal/ pediatric cohort in severe hemophilia A; 2) provide data management, laboratory, and biospecimen support necessary for the establishment of a unique and sharable biospecimen resource annotated with robust intergenerational clinical and demographic data to enable future studies of FVIII immunogenicity; and 3) develop and implement protocols and procedures to conduct hypothesis-driven research studies utilizing data and biospecimens from the antenatal/neonatal/pediatric cohort. The role of HARP is to provide overall project coordination, administration, data and biospecimen management, research protocols and procedures development and implementation, biostatistics/data analytics support; as well as laboratory (including multi-omics) and biorepository expertise for development of this unique intergenerational cohort and resource. HARP, in collaboration with the consortium of clinical centers, will lead the scientific development, pragmatic implementation, and expert conduct of the hypothesis-driven protocols that will permit the establishment of the severe Hemophilia A intergenerational cohort, utilization of some of the cohort longitudinal data and biospecimens, and establishment of a shareable resource for the scientific community.
Funding Opportunity PA-21-267 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ's Center for Quality Improvement and Patient Safety (CQuIPS) works to ensure patient safety in multiple settings with recent efforts to increase the development of processes including measures, metrics, tools and practices to increase patient safety in the ambulatory care setting and in long-term care facilities.
Notice NOT-HL-21-032 from the NIH Guide for Grants and Contracts
Notice NOT-OH-21-015 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-080 from the NIH Guide for Grants and Contracts
Notice NOT-HL-21-031 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-020 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-112 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-113 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-114 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-251 from the NIH Guide for Grants and Contracts. This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.
Funding Opportunity PAR-21-252 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups , including low-income, lower-middle-income, and upper-middle-income countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.
Funding Opportunity RFA-DA-22-040 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
Funding Opportunity RFA-DA-22-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of ?9-tetrahydrocannabinol (THC) that is present in cannabis and cannabis products.
Funding Opportunity RFA-DA-22-039 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of ?9-tetrahydrocannabinol (THC) that is present in cannabis and cannabis products.
Notice NOT-OD-21-184 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-22-009 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications that address the unmet need to detect cognitive impairment, including dementia, in large and diverse populations seen in primary care across the United States, including in health disparities populations, when a patient, relative, or care provider indicates concern. Proposed clinical paradigms should utilize tools that are simple to use, standardized, and ideally take five minutes or less to administer in a primary care clinical setting.
Funding Opportunity PAR-21-330 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.